COVID-19 Influenza A+B RSV Combo Test

The BioAid SARS-CoV-2 & Influenza A+B & RSV Combo Antigen Rapid Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and Respiratory Syncytial Virus (RSV) protein antigens. This test is for professional in vitro diagnostic use only. This test is only for individuals with sign and symptoms of respiratory infection consistent with COVID-19 within the first six (6) days of symptom onset when tested at least twice over three days with at least 48 hours between tests.

Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2, influenza and RSV can be similar. Results are for the simultaneous identification of SARS-CoV-2, influenza A virus, influenza B virus and Respiratory Syncytial Virus protein antigens, but do not differentiate between SARS-CoV and SARS-CoV-2 viruses and are not intended to detect influenza C antigens.

The viral antigens targeted by this test are generally detectable from specimens collected using nasal swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status.

Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of the disease. Individuals who test positive with the BioAid SARS-CoV-2 & Influenza A+B & RSV Combo Antigen Rapid Test should self-isolate and seek follow up care with their physician or healthcare provider as additional testing may be necessary.

All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2, influenza A, influenza B and RSV infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions such as isolating from others and wearing masks. Negative results should be considered in the context of an individual's recent exposures, history, and the presence of clinical signs and symptoms consistent with SARS-CoV-2, influenza A, influenza B and RSV infection.

Individuals who test negative and continue to experience SARS-CoV-2 and/or influenza-like symptoms of fever, cough and/or shortness of breath may still have SARS-CoV-2 and/or influenza infection and should seek follow up care with their physician or healthcare provider.

Influenza viruses belong to the Orthomyxoviridae family and cause the majority of viral lower respiratory tract infections. Influenza A and B are a significant cause of morbidity and mortality worldwide, considering that elderly and compromised individuals are especially at risk of developing severe illness and complications such as pneumonia. People feel some or all of these symptoms: fever or feeling feverish/chills, cough, sore throat, nasal stuffiness and discharge, myalgia, headaches, and anorexia. The influenza viruses can be spread from person to person in two different ways: through the air (large droplets and aerosols from sneezing and coughing), and by direct or indirect contact.

Human Respiratory Syncytial Viruses (RSV) belong to the Paramyxoviridae family and are the most important viral agents of acute respiratory infections. RSV is an enveloped, nonsegmented, negative, single stranded linear RNA genome virus. Respiratory Syncytial Virus is a common contributor of respiratory infections causing bronchitis, pneumonia, and chronic obstructive pulmonary infections in people of all ages. People often feel some or all of these symptoms: rhinorrhea, low-grade fever, cough, sore throat, headache, and wheezing.

RSV is transmitted via large nasopharyngeal secretion droplets from infected individuals, close contact, or self-inoculation after touching contaminated surfaces. Diagnosis can be problematic, as a wide range of pathogens can cause acute respiratory infections presenting with similar clinical syndromes.

There is a growing body of evidence that rapid detection of viral respiratory infections through testing patients as soon as possible after they are admitted to hospital allows more timely and targeted management of illness. For example, antiviral drugs may be started more quickly and appropriately and unnecessary antibiotics stopped earlier. Additionally, rapid diagnosis may offer the potential to decrease transmission to other patients and staff by rapid instigation of relevant infection prevention and control precautions, and may assist clinicians to make decisions earlier regarding discharge of infected patients, potentially reducing their length of stay in hospital and easing pressure on hospital beds.

The symptoms and signs of influenza may overlap with those seen with other respiratory pathogens, making diagnosis based on clinical presentation alone challenging. Diagnostic testing is therefore useful to guide appropriate clinical management, with the current gold-standard being detection of viral RNA by reverse transcriptase polymerase chain reaction (RT-PCR), conducted in a specialised laboratory. However, although RT-PCR can produce a result within 4–8 h, transportation to the laboratory and batching of specimens the time to receipt of result may be considerable longer.

Point-of care (POC) tests are medical diagnostic tests performed by healthcare professionals on the ward who are trained in the use of the point-of-care analyser machines but are not laboratory staff. Results are available soon after testing.

étiquette à chaud: covid-19 influenza a+b rsv combo test, China covid-19 influenza a+b rsv combo test manufacturers, suppliers, factory